Within the neuroanatomically based clusters, stacking a blood-based biomarker (IL-1 receptor antagonist, CRP, tumor necrosis factor α, BDNF, and transforming growth factor β) SVM model to a symptom data (baseline Positive and Negative Syndrome Scale, Beck Depression Inventory, and GAF-S individual item scores) SVM model (i.e., a combined model) increased accuracy for predicting symptomatic recovery at 9 months (GAF-S), with BAC of 71.2% for cluster 1% and 57.0% for cluster 2. Here, BDNF is linked to major depressive disorder.